Active, not recruitingPhase 3NCT05505916
An Open-label Extension Trial to Evaluate the Long-term Safety of KVD900 (Sebetralstat) for On-Demand Treatment of Angioedema Attacks in Adolescent and Adult Patients With Hereditary Angioedema (HAE)
Studying Hereditary angioedema
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- KalVista Pharmaceuticals, Ltd.
- Principal Investigator
- Study DirectorKalVista Pharmaceuticals, Ltd.
- Intervention
- KVD900 600 mg(drug)
- Enrollment
- 145 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2022 – 2026
Study locations (19)
- KalVista Investigative Site, Scottsdale, Arizona, United States
- KalVista Investigative Site, Little Rock, Arkansas, United States
- KalVista Investigative Site, San Diego, California, United States
- KalVista Investigative Site, Santa Monica, California, United States
- KalVista Investigative Site, Centennial, Colorado, United States
- KalVista Investigative Site, Colorado Springs, Colorado, United States
- KalVista Investigative Site, Evansville, Indiana, United States
- KalVista Investigative Site, Overland Park, Kansas, United States
- KalVista Investigative Site, Louisville, Kentucky, United States
- KalVista Investigative Site, Chevy Chase, Maryland, United States
- KalVista Investigative Site, Plymouth, Minnesota, United States
- KalVista Investigative Site, St Louis, Missouri, United States
- KalVista Investigative Site, Charlotte, North Carolina, United States
- KalVista Investigative Site, Cincinnati, Ohio, United States
- KalVista Investigative Site, Toledo, Ohio, United States
- +4 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05505916 on ClinicalTrials.govOther trials for Hereditary angioedema
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07298447Donidalorsen Treatment in Children With Hereditary AngioedemaIonis Pharmaceuticals, Inc.
- RECRUITINGNANCT07559630Single-center Randomized Controlled Trial of Rectal Arterial Embolization vs Band Ligation for the Treatment of Internal hemOrrhoidSJessica K. Stewart, MD
- RECRUITINGPHASE3NCT07428499Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)ADARx Pharmaceuticals, Inc.
- RECRUITINGNANCT07251933A Study of Lanadelumab in Children With Hereditary Angioedema (HAE) in Multiple CountriesTakeda
- ENROLLING BY INVITATIONPHASE3NCT07204938A Long-Term Study of Navenibart in Participants With Hereditary AngioedemaAstria Therapeutics, Inc.
- RECRUITINGPHASE3NCT06960213STOP-HAE: A Phase 3 Study of ADX-324 in HAEADARx Pharmaceuticals, Inc.
- RECRUITINGNANCT07001280A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)CSL Behring
- RECRUITINGPHASE3NCT06842823A Study of Navenibart in Participants With Hereditary AngioedemaAstria Therapeutics, Inc.